Safety of a mRNA COVID-19 Vaccine in Patients with Indolent Systemic Mastocytosis

Joana Gouveia; Maria Alexandra Rodrigues; Iolanda Fernandes; Renata Cabral; Helena Falcão

doi:10.20344/amp.20851

Safety of a mRNA COVID-19 Vaccine in Patients with Indolent Systemic Mastocytosis

Authors

Joana Gouveia Serviço de Imunoalergologia. Centro Hospitalar Universitário de Santo António. Porto.
Maria Alexandra Rodrigues Serviço de Dermatologia. Centro Hospitalar Universitário de Santo António. Porto.
Iolanda Fernandes Serviço de Dermatologia. Centro Hospitalar Universitário de Santo António. Porto; Consulta Multidisciplinar de Linfomas Cutâneos e Mastocitoses. Centro Hospitalar Universitário de Santo António. Porto; Unidade Multidisciplinar de Investigação Biomédica. Instituto de Ciências Biomédicas Abel Salazar. Universidade do Porto. Porto.
Renata Cabral Serviço de Imunoalergologia. Centro Hospitalar Universitário de Santo António. Porto.
Helena Falcão Serviço de Imunoalergologia. Centro Hospitalar Universitário de Santo António. Porto.

DOI:

https://doi.org/10.20344/amp.20851

Keywords:

COVID-19/immunology, COVID-19 Vaccines, Mastocytosis, Systemic/immunology, RNA, Messenger

Abstract

N/a.

Downloads

Download data is not yet available.

References

Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014;34:283-95.

Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA. 2021;325:780.

Rama TA, Moreira A, Castells M. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis. J Allergy Clin Immunol. 2021;147:877-8.

Giannetti MP, Olivieri F, Godwin G, Weller E, Nicoloro-SantaBarbara J, Bonadonna P, et al. Outcomes of COVID-19 vaccination in 323 patients with clonal and non-clonal mast cell activation disorders. Allergy. 2023;78:301-4.

Kaakati R, Khokhar D, Akin C. Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. J Allergy Clin Immunol Pract. 2021;9:3198-9.

Downloads

Published

2024-03-01

How to Cite

Gouveia J, Rodrigues MA, Fernandes I, Cabral R, Falcão H. Safety of a mRNA COVID-19 Vaccine in Patients with Indolent Systemic Mastocytosis. Acta Med Port [Internet]. 2024 Mar. 1 [cited 2024 Apr. 27];37(3):224-5. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/20851

Download Citation

Issue

Vol. 37 No. 3 (2024): March

Section

Letters to the Editor

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.